http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-PA02005667-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5da0fe9266d0323c730566a3e69144
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22
filingDate 2000-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6632bfde0959bf19ac1b93288ff9efa4
publicationDate 2004-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-PA02005667-A
titleOfInvention GALANTAMINE AND LICORAMINE ANALOGS AS MODULATORS OF NICOTINIC RECEPTORS.
abstract The analogues of galantamine and lycoramine are useful in the modulation of nicotinic receptors in humans and other animals. Modulation of these receptors is useful in the treatment and / or prevention of a variety of conditions that include the treatment of attention disorders, the provision of assistance to smokers and in the treatment of Parkinson's disease.
priorityDate 1999-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443723
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554252
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505226
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9651

Total number of triples: 39.